trial

Cromoglicate Adjunctive Therapy for Outpatients With Schizophrenia

NCTId NCT03794076
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1, Phase 2 · Recruiting
Enrollment 160 (estimated)
Sponsored by Vishwajit Nimgaonkar, MD PhD
Primary completion 2028-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1, Phase 2
Status
Recruiting
Enrollment
160 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Quadruple
Start
2019-04-01
Primary completion
2028-01
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Cromoglycate

Sponsors

Vishwajit Nimgaonkar, MD PhDLead Sponsor
Stanley Medical Research InstituteCollaborator

Investigators

1
Vishwajit L. Nimgaonkar, M.D., Ph.D.Principal Investigator

Sites

1 total
Pittsburgh, United States

Linked catalysts

1
Cromoglicate Adjunctive Therapy for Outpatients With Schizophrenia — primary completion2028-01

Facts & assertions

4 sourced
Enrollment
160
Phase
PHASE1,PHASE2
Primary Completion Date
2028-01
Status
RECRUITING
relationships
The graph out of here
drug
Cromoglycate
drug
lead_sponsor
Vishwajit Nimgaonkar, MD PhD
company
collaborator
Stanley Medical Research Institute
company
indication
Schizophrenia
indication
Schizo Affective Disorder
indication
Schizophrenia
indication
investigator
Vishwajit L. Nimgaonkar, M.D., Ph.D.
person